Literature DB >> 33305711

Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: A Systematic Review.

Aladeen Alloubani1, Refat Nimer2, Rama Samara3.   

Abstract

BACKGROUND: Globally, dyslipidemia has been shown to be an independent predictor of many cardiovascular and cerebrovascular events, which led to recent advocacy towards dyslipidemia prevention and control as a key risk factor and its prognostic significance to reduce the burden of stroke and myocardial infarction (MI). AIMS: This study aimed to evaluate hyperlipidemia as a risk factor connected with stroke and CVD. Moreover, having identified this risk factor, the study evaluates how hyperlipidemia has been examined earlier and what can be done in the future.
METHODS: All prospective studies concerning hyperlipidemia as risk factors for stroke and CVD were identified by a search of PubMed/MEDLINE and EMBASE databases with keywords hyperlipidemia, risk factors, stroke, and cardiovascular disease.
RESULTS: The constant positive association between the incidence of coronary heart disease and cholesterol concentration of LDL is apparent in observational studies in different populations. Thus, the reduction of LDL cholesterol in those populations, particularly with regard to initial cholesterol concentrations, can reduce the risk of vascular diseases. However, the impact of using lipid-lowering drugs, such as statins, has been demonstrated in several studies as an important factor in decreasing the mortality and morbidity rates of patients with stroke and CVD.
CONCLUSION: After reviewing all the research mentioned in this review, most studies confirmed that hyperlipidemia is a risk factor for stroke and correlated in patients with CVD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Hyperlipidemia; cardiovascular and cerebrovascular events.; cardiovascular disease; dyslipidemia; risk factors; stroke

Mesh:

Substances:

Year:  2021        PMID: 33305711      PMCID: PMC8950504          DOI: 10.2174/1573403X16999201210200342

Source DB:  PubMed          Journal:  Curr Cardiol Rev        ISSN: 1573-403X


  62 in total

1.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

2.  Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.

Authors:  Kwang Kon Koh; Pyung Chun Oh; Ichiro Sakuma; Yonghee Lee; Seung Hwan Han; Eak Kyun Shin
Journal:  Int J Cardiol       Date:  2016-07-05       Impact factor: 4.164

3.  Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Authors:  Marshall B Elam; Henry N Ginsberg; Laura C Lovato; Marshall Corson; Joseph Largay; Lawrence A Leiter; Carlos Lopez; Patrick J O'Connor; Mary Ellen Sweeney; Daniel Weiss; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard Grimm; Faramarz Ismail-Beigi; David C Goff; Jerome L Fleg; Yves Rosenberg; Robert P Byington
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

4.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.

Authors:  Paul M Ridker; Nader Rifai; Nancy R Cook; Gary Bradwin; Julie E Buring
Journal:  JAMA       Date:  2005-07-20       Impact factor: 56.272

5.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

6.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

Authors:  Jane Armitage; Louise Bowman; Karl Wallendszus; Richard Bulbulia; Kazem Rahimi; Richard Haynes; Sarah Parish; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

8.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke.

Authors:  Michael V Holmes; Iona Y Millwood; Christiana Kartsonaki; Michael R Hill; Derrick A Bennett; Ruth Boxall; Yu Guo; Xin Xu; Zheng Bian; Ruying Hu; Robin G Walters; Junshi Chen; Mika Ala-Korpela; Sarah Parish; Robert J Clarke; Richard Peto; Rory Collins; Liming Li; Zhengming Chen
Journal:  J Am Coll Cardiol       Date:  2018-02-13       Impact factor: 24.094

9.  The Relationship Between Premature Myocardial Infarction with TC/HDL-C Ratio Subgroups in a Multiple Risk Factor Model.

Authors:  Zinat Nadia Hatmi; Nasrin Jalilian; Ali Pakravan
Journal:  Adv J Emerg Med       Date:  2019-05-12

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  8 in total

1.  Associations between residential greenness and blood lipids in Chinese elderly population.

Authors:  J Xu; X Yuan; W Ni; Y Sun; H Zhang; Y Zhang; P Ke; M Xu; Z Zhao
Journal:  J Endocrinol Invest       Date:  2022-07-19       Impact factor: 5.467

2.  Association of blood lipids with coronary artery plaque among Saudi patients referred to computed tomography.

Authors:  Sumaya Al Helali; Muhammad Abid Hanif; Ahmad Al Majed; Nura Alshugair; Abdullah Belfageih; Hamad Al Qahtani; Sameer Al Dulikan
Journal:  BMC Cardiovasc Disord       Date:  2022-06-03       Impact factor: 2.174

3.  Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study.

Authors:  Ni Tien; Tien-Yuan Wu; Cheng-Li Lin; Chia-Jui Wu; Chung-Y Hsu; Yi-Jen Fang; Yun-Ping Lim
Journal:  Front Med (Lausanne)       Date:  2022-06-13

4.  Pelargonidin ameliorates MCAO-induced cerebral ischemia/reperfusion injury in rats by the action on the Nrf2/HO-1 pathway.

Authors:  Kong Fu; Miancong Chen; Hua Zheng; Chuanzi Li; Fan Yang; Qian Niu
Journal:  Transl Neurosci       Date:  2021-01-12       Impact factor: 1.757

5.  Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.

Authors:  Toshimitsu Tanaka; Hiroyuki Suzuki; Keisuke Miwa; Tomoyuki Ushijima; Sachiko Nagasu; Masaru Fukahori; Kaito Ishii; Toru Nakamura; Hideki Iwamoto; Atsutaka Masuda; Takahiko Sakaue; Hironori Koga; Yoshito Akagi; Kenta Murotani; Takuji Torimura
Journal:  Oncol Lett       Date:  2022-07-19       Impact factor: 3.111

6.  Identification of immune-related key genes in the peripheral blood of ischaemic stroke patients using a weighted gene coexpression network analysis and machine learning.

Authors:  Peng-Fei Zheng; Lu-Zhu Chen; Peng Liu; Hong Wei Pan; Wen-Juan Fan; Zheng-Yu Liu
Journal:  J Transl Med       Date:  2022-08-12       Impact factor: 8.440

Review 7.  Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders.

Authors:  Hongxiang Hong; Xu Lu; Qun Lu; Chao Huang; Zhiming Cui
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

Review 8.  Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions.

Authors:  Ana Rita de Oliveira Dos Santos; Bárbara de Oliveira Zanuso; Vitor Fernando Bordin Miola; Sandra Maria Barbalho; Patrícia C Santos Bueno; Uri Adrian Prync Flato; Claudia Rucco P Detregiachi; Daniela Vieira Buchaim; Rogério Leone Buchaim; Ricardo José Tofano; Claudemir Gregório Mendes; Viviane Alessandra Capelluppi Tofano; Jesselina F Dos Santos Haber
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.